Akoya Biosciences Inc (AKYA)
2.86
+0.15
(+5.54%)
USD |
NASDAQ |
Sep 27, 16:00
2.86
0.00 (0.00%)
After-Hours: 20:00
Akoya Biosciences SG&A Expense (Annual): 82.38M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 82.38M |
| December 31, 2022 | 79.65M |
| December 31, 2021 | 51.02M |
| Date | Value |
|---|---|
| December 31, 2020 | 23.98M |
| December 31, 2019 | 26.35M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
23.98M
Minimum
2020
82.38M
Maximum
2023
52.68M
Average
51.02M
Median
2021
SG&A Expense (Annual) Benchmarks
| Bruker Corp | 730.10M |
| Azenta Inc | 316.28M |
| Harvard Bioscience Inc | 46.89M |
| Bionano Genomics Inc | 93.50M |
| Singular Genomics Systems Inc | 54.48M |